Business
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline progress, reiterated key anticipated milestones, and reported first quarter 2026 financial results.
About this update from Nuvalent, Inc.
[{"type":"text","content":"NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC ","length":75,"tagName":"p","attribs":{}},{"type":"text","content":"NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review with PDUFA target action date of September 18, 2026","length":137,"tagName":"p","attribs":{}},{"type":"text","content":"Submission for potential label expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC planned for the second half of 2026","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"Strengthened leadership team with key internal promotions","length":57,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., May 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline progress, reiterated key anticipated milestones, and reported first quarter 2026 financial results.","length":345,"tagName":"p"},{"type":"image","alt":"Nuvalent, Inc. (PRNewsfoto/Nuvalent, Inc.)","displaySize":"","headline":null,"caption":"Nuvalent, Inc. (PRNewsfoto/Nuvalent, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":119,"url":"https://media.zenfs.com/en/prnewswire.com/006d4b5652d5dd7204d997761f53cb52"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RCK_1lPKTaWgCmt5M44.EA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMA--/https://media.zenfs.com/en/prnewswire.com/006d4b5652d5dd7204d997761f53cb52","width":400,"height":119},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/muartoS3T3IS6FPwQyIAXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE5MA--/https://media.zenfs.com/en/prnewswire.com/006d4b5652d5dd7204d997761f53cb52","width":400,"height":119}},"href":"https://mma.prnewswire.com/media/1583941/Nuvalent_Inc_Logo_2024.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""The forward momentum continues at Nuvalent, with both of our parallel-lead programs advancing toward key US regulatory milestones and the opportunity to bring our first new medicine to patients this year," said James Porter, Ph.D., Chief Executive Officer of Nuvalent. "We recently submitted our NDA for neladalkib in TKI pre-treated ALK-positive NSCLC and are continuing to build our comm...